- Mechanism
- Inhibits NF-kB activation to reduce inflammation
- Typical research dose
- 1-5 mg/kg (animal models)
- Route
- oral, topical
- Half-life
- Unknown (rapidly degraded)
- Legal status
- Research Only
Overview
KPV peptide (Lysine-Proline-Valine) is a naturally occurring tripeptide derived from the C-terminal region of alpha-melanocyte-stimulating hormone (alpha-MSH). It possesses potent anti-inflammatory and antimicrobial properties without inducing the pigmentation effects typically associated with full-length alpha-MSH. By modulating key inflammatory pathways, KPV offers a targeted approach to cellular repair, making it highly valuable for researching inflammatory bowel diseases and dermatological conditions.
Potential Benefits
- Gut Inflammation Reduction: KPV significantly reduces intestinal inflammation and protects against colitis-associated cancer when mediated by the PepT1 transporter (Viennois et al., 2016).
- Accelerated Wound Healing: The peptide promotes skin repair and reduces pathological stress responses, showing efficacy in treating severe thermal injuries (Liu et al., 2002).
- Antimicrobial Activity: Research indicates KPV exhibits strong antimicrobial properties against common pathogens like Staphylococcus aureus and Candida albicans, aiding in infection control (Luger et al., 2003).
- Dermatological Repair: Topical and transdermal delivery of KPV effectively targets localized skin inflammation, offering potential treatments for psoriasis and dermatitis (Pawar et al., 2017).
- Immune System Modulation: By inhibiting the NF-kB pathway, KPV regulates immune responses and decreases the production of pro-inflammatory cytokines without suppressing overall immune function.
Where to Buy KPV
Research compound. KPV is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Mild gastrointestinal discomfort when taken orally
- Temporary redness or erythema at the topical application site
- Slight nausea during initial dosing phases
- Mild headache following systemic administration
- Local skin irritation from transdermal patches
Rare or serious side effects:
- Allergic reactions or hypersensitivity to the peptide sequence
- Unintended immune modulation in severely immunocompromised subjects
- Potential interactions with systemic immunosuppressant medications
KPV is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Intracellular signaling modulation is the primary mechanism by which KPV exerts its anti-inflammatory effects. Upon entering the cell, often facilitated by transporters like PepT1 in the gastrointestinal tract (Viennois et al., 2016), the peptide translocates to the nucleus to inhibit the activation of NF-kB. This inhibition prevents the transcription of pro-inflammatory cytokines, chemokines, and adhesion molecules, effectively halting the inflammatory cascade at the genetic level.
Receptor-independent activity distinguishes KPV from its parent hormone, alpha-MSH. While alpha-MSH binds to melanocortin receptors to induce pigmentation and other systemic effects, KPV bypasses these receptors to deliver localized anti-inflammatory and antimicrobial KPV benefits. This targeted action allows for high-dose therapeutic applications in tissues like the gut and skin without triggering unwanted melanogenic or systemic endocrine side effects.
Origin & History
Discovery and structural isolation of KPV occurred during extensive research into the melanocortin system and the anti-inflammatory properties of alpha-MSH. Scientists identified that the C-terminal tripeptide sequence (Lysine-Proline-Valine) retained the parent hormone's immunomodulatory capabilities while shedding its pigment-inducing traits. This structural truncation represented a major milestone, allowing researchers to isolate the therapeutic KPV benefits of alpha-MSH for targeted clinical applications.
Development and regulatory status of KPV have primarily focused on its formulation for localized delivery, including oral capsules for gut health and topical creams for dermatological use. Advanced delivery methods, such as transdermal iontophoresis, have been developed to enhance its penetration across human skin (Pawar et al., 2017). Currently, KPV remains an investigational compound and is classified as a research-only chemical, lacking formal approval from the FDA for human medical use.